Nirav S. Dhruva, MD
A better understanding of the molecular characteristics of non–small cell lung cancer (NSCLC) has led to improved outcomes for patients with the disease, said Nirav S. Dhruva, MD. However, more research is needed to understand resistance mechanisms and determine which PD-L1 expression test is best suited for each patient.
“Arguably the biggest advance we've made in NSCLC over the past few years has been in our ability to learn more about tumors and their characteristics,” said Dhruva. “[Now] we can better tailor treatments to patients, and as such, we [are seeing] better toxicity profiles, better efficacy, and ultimately, [we’re helping] patients live longer.”
Through improved understanding of changes in NSCLC cells that help them proliferate in the body, several targeted therapies for alterations such as EGFR
, and ROS1
have emerged in the paradigm, leading to improved survival outcomes. Beyond these agents, immunotherapy has become a mainstay in the frontline setting.
... to read the full story